Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets

Alessio Filippo Peritore 1,†, Rosalba Siracusa 1,†, Rosalia Crupi 1 and Salvatore Cuzzocrea 1,2,*

1 Department of Chemical Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, Italy
2 Department of Pharmacological and Physiological Sciences, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
* Correspondence: salvator@unime.it
† The first two authors contributed equally to this study.

Received: 15 July 2019; Accepted: 5 September 2019; Published: 11 September 2019

Abstract: The use of a complete nutritional approach seems increasingly promising to combat chronic inflammation. The choice of healthy sources of carbohydrates, fats, and proteins, associated with regular physical activity and avoidance of smoking is essential to fight the war against chronic diseases. Among the molecules that contribute to the analgesic, anti-inflammatory, or antioxidant action of the diets, there are numerous molecules, among which some of a lipidic nature very active in the inflammatory pathway. One class of molecules found in diets with anti-inflammatory actions are ALIAmides. Among all, one is particularly known for its ability to counteract the inflammatory cascade, the Palmitoylethanolamide (PEA). PEA is a molecular that is present in nature, in numerous foods, and is endogenously produced by our body, which acts as a balancer of inflammatory processes, also known as endocannabionoid-like. PEA is often used in the treatment of both acute and chronic inflammatory pathologies, either alone or in association with other molecules with properties, such as antioxidants or analgesics. This review aims to illustrate an overview of the different diets that are involved in the process of opposition to the inflammatory cascade, focusing on the capacity of PEA and new formulations in synergy with other molecules.

Keywords: Palmitoylethanolamide; ALIAmide; NAcylethanolamide

1. Introduction

Inflammation itself is not a negative mechanism. Indeed, it is the first biological response of our organism to an external aggression. It is functional to the state of health when it is aimed at a specific biological event, when it has a start time and of precise resolution, when the intensity is limited, and when the pain that accompanies it does not interfere with the quality of everyday life. Inflammatory processes are usually triggered by an attack by physical agents (such as an injury, trauma, or burn), toxic, chemical, or biological (such as bacteria and viruses). The duration of the inflammation depends on the time that is needed to eliminate the harmful cause and to repair the damage. It can be short (hours or days) or it can last months or years. In the second case, the inflammatory processes, from defensive become a harmful mechanism [1]. Inflammation becomes pathological when an imbalance is created in the relationship between pro-inflammatory and anti-inflammatory mediators in a sort of adaptive mechanism to a person’s permanent exposure to stress factors, so the inflammation continuously triggers anti-inflammatory responses. Therefore, chronic inflammation, which lasts over time, causes several problems to both affected organs and those (“comorbidity”) [2]. It is widely accepted that old age is characterized by a low-grade and chronic inflammatory state, which
has been called inflammaging [3–5]. In addition, it is believed that inflammation is at the beginning of several diseases, including obesity, cancer, neurodegenerative, and cardiovascular diseases [6]. Ultimately, the percentage of people suffering from inflammation and pain of various kinds is very high. Sometimes, these conditions are so extreme that they are disabling. For this reason, and for rapid relief, synthetic anti-inflammatory drugs (drugs) are often used. Treatment with the emergency drug may be useful, but people who use this solution usually do so in a recurrent and routine manner causing addiction and worsening the general condition of the body. Therefore, it is always good to make prevention your weapon to avoid resorting to solutions that in the immediate will relieve us from the inflammation, but that then, on the other hand, will damage us even more [7,8]. In this context, a good diet can offer an excellent alternative to the traditional drug. In fact, there are foods that have some wonderful anti-inflammatory and antioxidant characteristics. Palmitoylethanolamide (PEA) is both a naturally occurring lipid ingredient contained in foods/dietary supplements and an endogenous lipid mediator belonging to the class of fatty acid ethanolamides [9]. Evidence indicates that PEA is an important anti-inflammatory, analgesic, and neuroprotective mediator acting on several molecular targets in both central and in peripheral organs and systems [10]. However, PEA lacks a direct antioxidant capacity to prevent the formation of free radicals, and to counteract the damage of DNA, lipids, and proteins. Therefore, in this review, we will see how the PEA in synergy with the natural antioxidant molecules that are present in some foods can have positive therapeutic effects, both on inflammatory processes and on oxidative stress.

2. N-Acylethanolamines and Diet

A class of important component that can be obtained through the diet are polyunsaturated fatty acids (PUFA), which play fundamental roles in numerous cellular processes, such as inflammation, immunity, or even neurotransmission. With the diet, it is essential to maintain a correct balance between the omega-6 (ω-6) PUFA and the PUFA ω-3. The typical Western diet contains an excess of ω-6 and at the same time a deficiency of ω-3s [11]. Arachidonic acid (AA) is the archetype ω-6, with 20 carbon atoms and four double bonds (20: 4ω-6). In western populations, there are numerous chronic diseases due to AA derivatives, such as pain and swelling that are caused by prostaglandins and bronchoconstriction and asthma by leukotrienes. PUFA ω-3 is intended to counteract the inflammatory metabolites of AA. Eicosapentaenoic acid (EPA, 20: 5ω-3) and docosahexaenoic acid (DHA, 22: 6ω-3) are two of the most well-known PUFA ω-3 that are able to counter the inflammatory metabolites of AA. Other AA derivatives are also some N-Acylethanolamines (NAEs), which are known molecules for their anti-inflammatory action. Numerous preclinical studies have shown that a massive integration of diet rich of AA causes the increase in serum levels of two of the best known NAEs, Anandamide (AEA) and 2-Arachidonoylglycerol (2-AG). The need for AA intake for the biosynthesis of the NAEs can therefore lead to a massive increase in the latter’s levels, and in the long run it can lead to a desensitization of the Cannabinoid receptor 1 (CB1) and a downregulation of the Cannabinoid receptor 2 (CB2) [12–14]. Linoleic acid, a PUFA 18: 2ω-6, is converted to AA, increase 2-AG and AEA levels, and induces obesity in mice [15]. The use of the dietary supplement that is based on ω-3s leads to an increase in the concentration of EPA and/or DHA in tissues, cells, and plasma, and at the same time a decrease in the concentration of AA in the same [16,17]. A diet that is rich in ω-3 markedly elevated the NAE metabolite of DHA, called DHEA, the NAE metabolite of EPA, called EPEA, and the sn-2 glycerol-ester metabolite of EPA, called 2-EPG [12,17]. DHEA and EPEA showed a high binding affinity for CB1 (Ki = 124 and 55 nM respectively) and acted as partial agonists, act like the endocannabinoids, and also DHEA is catabolized by fatty acid amide hydrolase (FAAH) [18]. Their affinity is almost the same as that of the AEA [19]. In natural fish oil, DHA and EPA are esterified in triacylglycerides (TAGs), while in many fish oil capsules, DHA and EPA are esterified into EE (ethyl ester) or TAG (rTAG). Krill oil contains both DHA and EPA, which are esterified in phospholipids, mainly phosphatidylcholine, which can improve their bioavailability; in addition, krill oil contains less AA than fish oil [20]. In another study it has been seen that the integration of milk formulas with AA
acid and docosahexaenoic acid (C22: 6n3, DHA) increases the concentrations of the corresponding NAE, AEA, and N-docosahexaenoyl-ethanolamine (22: 6n3 NAE) in specific brain regions of newborn piglets, Ref. [12], while 2-AG levels have not been changed. In the same study, mice that were fed an AA-rich diet from the post-natal day 1-58 exhibited an increase in AEA concentrations in the whole brain [12]. In a study [13], see that after a diet deficient of ω-3 PUFA, mice show higher level of 2-AG in the brain, while in another study a decrease of 2-AG brain levels can be seen after short-term supplementation of DHA-rich fish oil (FO) as compared with the diet supplemented with low n-3 PUFA. It has been found that the presence in the diet of some unusual fatty acids, such as conjugated linoleic acid (CLA), is linked with changes in the cerebral endocannabinoid levels. In fact, in 3-wk-old mice, they were fed diets containing 3% LA or CLA for four weeks. The amount of 2-AG, but not anandamide, OEA and PEA, in the cerebral cortex, but not the hypothalamus, was significantly decreased by treatment with CLA as compared to LA [21]. Furthermore, the authors of this study used LA, the biosynthetic precursor of AA, as a control fatty acid and, as a consequence, the CLA diet was 3% lower than LA when compared to controlling the diet, thus probably influencing both levels of AA and 2-AG of the brain, also independently of dietary CLA. In the summary, the possible effects of CLA on endocannabinoids should be studied while using lower doses and another adequate control diet.

3. ALIAmides, PEA and Food

One family of molecules involved in neuroinflammation is the ALIAmides family. The acronym ALIAmides derives from the definition Autacoid Local Injury Antagonist amides (ALIAmides) coined for the first time by the group of Rita Levi Montalcini describing a group of endogenous bioactive acyl ethanolamides with anti-inflammatory properties, such as the renowned palmitoyl ethanolamide (PEA), or stearoyl ethanolamide (SEA) and oleoyl ethanolamide (OEA) [22]. N-(2-hydroxyethyl)-exadecanamide, commonly known as palmitoylethanolamide (PEA), belongs to the N-acylethanolamine family (NAE). During a study that was conducted in 1950, some researchers found that patients, in that case less privileged children, which were subjected to a diet rich of dry chicken and egg yolk did not contract rheumatic fever. Looking further into the study, they noted that the purified lipid fraction of egg yolk was responsible for the anti-inflammatory action [23,24]. Only in 1957 did they understand that it was the PEA that exerted the anti-inflammatory action, present not only in egg yolk, but also in other foods, such as soy oil, peanut oil, and corn. The potential therapeutic use of PEA has led many researchers to identify other natural sources that are rich in this compound. In fact, PEA has also been found in the seeds of some varieties of legumes, such as peas and beans [25,26], as well as in some varieties of vegetables, such as tomatoes and potatoes [25,27]. Finally, high levels of PEA were also found in human, bovine, and moose milk [28,29]. PEA, like endocannabinoids, is an endogenous lipid molecule 25 that is produced “on demand” by most of the body’s cells and tissues, and it acts as a balancer in those processes that are associated with neuro-inflammation [10,30,31].

4. Diet Modify PEA Levels

A different treatment strategy might consider the function of diets on the endogenous levels of PEA, as PEA is the ester between palmitic acid and ethanolamine. Probably, increasing the intake of one of these two compounds through the diet could increase the levels of the PEA itself. Our body produces endogenous palmitic acid, but at the same time it can be found in different dates. Various foods possess palmitic acid, such as foods that are rich in animal fat triglycerides, various vegetable oils, such as cottonseed oil or palm oil. It was shown that no effect on the three groups of fatty acids, the dietary saturated fatty acids, the monounsaturated fatty acids, and the polyunsaturated fatty acids, in membrane phospholipids after extensive changes in the ratio of these three groups, but at the same time considerable influence on fatty acid composition of adipose tissue and plasma triglycerides [32]. No effect on PEA levels in the brain and liver, as well as in the percentage of palmitic acid in fatty acid composition of bulk phospholipids of the same two tissues, was shown after one week feed rats with high-fat-diet, enriched with 9.3-fold with palmitic acid [33]. Dietary fat was found to decrease
the levels of PEA in the small intestine (jejunum), furthermore after fed with palmitic acid-rich palm oil, the PEA levels in jejunum did also decrease, but the PEA levels decrease was little less than other NAEs. In another study, it was observed [34] that high dietary fat for eight weeks decreased the PEA levels in the small intestine of mice, but not after 14 weeks of high-fat diet. To date, no data exists regarding the effect of dietary ethanolamine on PEA or other NAE tissue levels, although it has been seen that the contribution of an ethanolamine supplement increases the levels in the brain of phosphatidylethanolamine and also in liver microsomes [35,36]

5. Biosynthesis, Degradation and Mechanism of Action of PEA

PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis [37,38]. PEA has been shown to inhibit peripheral inflammation and mast-cell degranulation, as well as to exert neuroprotective and antinociceptive effects in rats and mice [37,38]. The biosynthesis of PEA occurs through a common enzyme for the other NAEs, the selective phospholipase N-acyl-phosphatidyl-ethanolamine D (NAPE-PLD), starting from the hydrolysis of the precursor N-palmitoyl-phosphatidyl-ethanolamine (NAPE) [39]. The degradation of PEA occurs through the action of two different enzymes: the first selective for PEA, the amidase of N-acyethanolamine-hydrolysing acid (NAAA), while the second, the FAAH enzyme, instead deputy to the hydrolysis not only of PEA, but also of the other NAEs [31,40,41]. The anti-inflammatory, anti-hyperalgesic, and neuroprotective effects of PEA can occur in different ways.

The pleiotropic action of PEA involves multiple mechanisms [10]. Over the years, several PEA action mechanisms have been hypothesized, which do not exclude each other. The first, as previously mentioned, is the ALIA mechanism proposed by the research group of Rita Levi Montalcini, hence the name of this family of molecules, according to which PEA acts as a down-regulator of mast cell activation [42,43]. From the earliest studies, it was clear that PEA acted as a neutralizer of mastocyte degranulation, and to understand how they occurred, a second mechanism of action was thought to provide a direct link to the CB2 receptor. Initially it was thought that PEA could act as a CB2 receptor agonist [44], a theory that was later contradicted by the research group of Sugiura et al. [45], which showed that the latter had a low affinity for the CB2 receptor, thus explaining why PEA action on this receptor was not blocked by CB2 antagonists [46]. By virtue of this low affinity to bind CB2 receptor, a further mechanism that was mediated by the PEA is proposed through the direct activation of two other receptor targets: the peroxisome proliferator-activated receptors α (PPAR-α), belonging to the nuclear receptor superfamily [47] and the orphan G protein-coupled receptor (GPR55) [48]. Finally, a further theory has been advanced, which does not exclude the previous ones, according to which the PEA through a mechanism called “entourage effect” that can act indirectly on cannabinoid receptors, in particular towards CB2 receptor explaining its activation, despite the low affinity [49–51]. Through this entourage effect, PEA can indirectly activate the CB2 and CB1 receptors [50,52], probably by increasing the levels of AEA and 2-AG, for example by inhibiting the expression of FAAH, the enzyme that is responsible for their degradation [50]. Similarly, PEA can indirectly activate type 1 vanilloid transient receptors (TRPV1) channel, an endogenous target of ALIAmides or increase AEA and 2-AG activation and desensitization of TRPV1 induced [49,51–54]. Recently, it has also been shown that PEA through PPAR-α receptors can increase the expression of CB2 receptors [55] and activate TRPV1 channels [56,57]. Finally it was also proposed that PEA could improve the activation and desensitization of the AEA and 2-AG of the TRPV1 channels through an allosteric modulation of TRPV1 (entourage effect) [49,50,52]. See biosynthesis and degradation in Figure 1 and molecular target and mechanism of action of PEA in Figure 2.
Figure 1. Metabolic pathways of palmitoylethanolamide (PEA). (A) PEA is biosynthesized from a membrane phospholipid, N-palmitoyl-phosphatidyl-ethanolamine (NPPE), through the direct hydrolysis by N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD). (B) PEA can be then degraded to palmitic acid and ethanolamine by either FAAH or selective enzyme NAAA [10].

Figure 2. Molecular target and mechanism of action of PEA. (A) PEA can directly activate PPAR-α [47] or (B) GPR55 [48]. (C) PEA through the inhibition of the expression of FAAH, may increase the endogenous levels of AEA and 2-AG, which directly activate CB2 (or CB1) receptors and TRPV1 channels (entourage effect) [50,52]. (D) PEA, probably through an allosteric modulation of TRPV1 channels, potentiates the activation and desensitization by AEA and 2-AG of TRPV1 channels (entourage effect) [10]. (E) PEA may also activate TRPV1 channels via PPAR-α [56,57], or increase CB2 receptor expression via PPAR-α [55].
6. PEA, Synergy with Natural Molecules with Antioxidant Properties

Among the molecules that the immune cells secrete in the tissues during the inflammatory processes, oxidizing agents play an important role in the innate immunity. However, oxidizing species in inflamed tissues produce a wide variety of harmful effects, the intensity of which contributes to pathological phenomena and broadens the intracellular response. The effects of highly reactive molecular species that were derived from oxygen and nitrogen to proteins, lipids, and nucleic acids cause tissue damage. Under conditions characterized by low-grade inflammation, the use of products able to minimize the toxic outcomes of reactive species of oxygen and nitrogen can contribute to the restoration of the tissue homeostasis. PEA lacks a direct antioxidant capacity to prevent the formation of free radicals, and to counteract the damage of DNA, lipids, and proteins. Furthermore, with its lipid structure and the large size of heterogeneous particles in the native state, PEA has limitations in terms of solubility and bioavailability. PEA has been micronized or ultra-micronized to overcome these problems. A major benefit of micro-crystallization is the enhanced rate of dissolution [58] and the rate of absorption of small drug particles is not influenced by the hydrodynamics in the gastro-intestinal tract an important factor in reducing variability of drug absorption when orally administered [58]. Impellizzeri et al. have tested these PEA formulations in carrageenan-induced inflammation in the rat paw extensively used in the development of anti-inflammatory drugs. Micronized and ultra-micronized PEA possessed superior pharmacological action against carrageenan-induced inflammatory pain, in contrast to the preparation of non-micronized PEA, which failed to show efficacy when orally given in this model [59]. The anti-inflammatory action of PEA combined with an antioxidant could potentiate its pharmacological effects [31]. Among the natural molecules that are able to counteract the peroxidation processes there are several flavonoids, such as Luteolin, Polydatin, Quercetin, and Silymarin, which possess various pharmacological actions and therapeutic applications.

6.1. PEA and Luteolin

Luteolin is a flavone that is normally present in glycosylated form in foods commonly present in the diet, such as celery, carrots, salad, spinach, onion, oregano, rosemary, green pepper, chamomile, olive oil, and in plants, such as honeysuckle, chrysanthemum morifolium, and burdock [60–63]. It has been shown that luteolin has numerous biological effects: among these, the protective effect on the oxidative processes involving DNA in the presence of free radicals [64,65] and anti-inflammatory and anti-oxidant effects [66]. Luteolin is one of the most powerful and effective polyphenols that are capable of inhibiting the production of proinflammatory cytokines and nitric oxide induced by lipopolysaccharide endotoxin [67,68]. The anti-inflammatory activity of Luteolin includes the activation of anti-oxidative enzymes, suppression of the nuclear factor (NF)-B pathway, and inhibition of pro-inflammatory substances [69]. The pharmacodynamic properties of PEA and those of flavonoids luteolin and polydatin appear complementary, which suggests that, if administered in combination, they can counteract the two main conspirators of chronic diseases: low-grade inflammation and oxidative stress. Based upon the findings obtained with micronized/ultra-micronized PEA, these experiments were carried out while utilizing a co-ultra-micronized PEA/Luteolin composite (co-ultraPEALut, prepared in a 10:1 mass ratio), again making use of jet milling technology. In a chronic corticosterone mouse model of anxiety/depression has been shown for the first time that co-ultraPEALut exerts a significant antidepressant effect at low doses. Furthermore, this compound improves hippocampal neurogenesis and neuroplasticity, which are elements that influence cognition [70]. The search for molecules that participate in neuroprotection has become important, especially for protecting the nervous tissue from secondary neurodegenerative events. In this regard, it has been shown that co-ultraPEALut exerts a protective role in a model of spinal cord organotypic cultures and an in vivo model. In particular, this study showed that co-ultraPEALut significantly reduces inflammation and oxidative stress associated with damage. Furthermore, this compound improves motor function and histological alteration caused by spinal cord injury in mice [71]. In addition, another study suggests that co-ultraPEALut treatment inhibits autophagic cell death induced at the lesion site in in vivo model of SCI [72]. Neuroprotective propriety of co-ultraPEALut have also been demonstrated on secondary inflammatory process and autophagy
involved in traumatic brain injury (TBI). In particular, co-ultraPEALut modulated apoptosis, the release of cytokine and reactive oxygen species, the activation of chymase, tryptase, and nitrotyrosine, and inhibited autophagy [73]. Unlike SCI and TBI, co-ultraPEALut has been shown to stimulate autophagy in in vivo and in vitro Parkinson’s disease model (PD). Treatment with co-ultraPEALut is able to modulate both the neuroinflammatory process and the autophagic pathway that is involved in PD, actions, which may underlie its neuroprotective effect [74]. Inflammatory processes and oxidative stress also play an important role in Alzheimer’s disease (AD). Therefore, the effect of co-ultraPEALut was investigated in an organotypic model of AD, both in vitro and ex vivo [75]. In demyelinating diseases, such as multiple sclerosis, it has been shown that oligodendrocytes are not able to repair damage to themselves or to other cells. Therefore, given that co-ultraPEALut is able to improve spinal injuries and those that are caused by head trauma, research was carried out to evaluate the ability of the compound to promote the maturation of undifferentiated oligodendrocyte precursor cells (OPC). The study found that co-ultraPEALut promotes the morphological development of OPC and the total protein content without affecting proliferation [76]. Oxidative stress has a crucial role in the pathogenesis of inflammatory diseases, such as rheumatoid arthritis. In this regard, co-ultraPEALut was tested in the mouse model of collagen-induced arthritis to assess its ability to counteract the inflammatory process. The study showed that the compound had protective effects, not only on inflammation, but also on cartilage and bone in the tibiotarsal joints of animals [77]. Given the protective capabilities of co-ultraPEALut many clinical trials have been performed. For example, the protective effect and the synergy between PEA and Luteolin have been evaluated in patients suffering from stroke [78], or in patients with autism [79], or in patients who, following hip rupture, showed neuropsychiatric disorders, such as delirium [80]. See the co-ultraPEALut molecular targets in Table 1.

Table 1. Co-ultraPEALut therapeutic actions and molecular targets: in vivo and in vitro study.

| Type of Study                   | Molecular Targets | References |
|--------------------------------|-------------------|------------|
| Mouse model of Anxiety/Depressive | BrdU ↑       | [70]       |
|                                | DCX ↑            |            |
|                                | BDNF ↑           |            |
|                                | Bax ↓            |            |
|                                | BeI-2 ↑          |            |
|                                | Cox-2 ↓          |            |
|                                | iNOS ↓           |            |
|                                | nNOS ↑           |            |
|                                | PPAR ↑           |            |
|                                | PPARβ/δ ↓        |            |
|                                | PPARγ ↓          |            |
|                                | Beclin-1 ↓       |            |
|                                | p62 ↓            |            |
|                                | MAP-LC3 ↓        | [71,72,81] |
|                                | mTOR ↑           |            |
|                                | p70S6K ↑         |            |
|                                | p-AKT ↑          |            |
| Mouse model of Spinal Cord Injury | BrdU ↑        |            |
|                                | DCX ↑            |            |
|                                | GFAP ↓           |            |
|                                | MAP-2 ↑          |            |
|                                | BDNF ↑           |            |
|                                | GDNF ↑           |            |
|                                | NGF ↑            |            |
|                                | NT-3 ↑           |            |
| Type of Study                                      | Molecular Targets       | References |
|---------------------------------------------------|-------------------------|------------|
| Mouse model of Rheumatoid Arthritis (CIA)         | Chymase ↓                | [77]       |
|                                                   | Tryptase ↓               |            |
|                                                   | Mast cells ↓             |            |
|                                                   | MIP-1α ↓                 |            |
|                                                   | MIP-2 ↓                  |            |
|                                                   | IL-1β ↓                  |            |
|                                                   | IL-6 ↓                   |            |
|                                                   | TNF-α ↓                  |            |
|                                                   | MPO activity ↓           |            |
|                                                   | Nitrotyrosine ↓          |            |
|                                                   | MDA ↓                    |            |
|                                                   | IkBa ↑                   |            |
|                                                   | NFkB p65 ↓               |            |
|                                                   | BDNF ↑                   |            |
|                                                   | GDNF ↑                   |            |
|                                                   | GFAP ↓                   | [75]       |
|                                                   | iNOS ↓                   |            |
|                                                   | nNOS ↑                   |            |
|                                                   | AIF ↓                    |            |
|                                                   | Caspase-3 ↓              |            |
|                                                   | PARP-1 ↓                 |            |
| In vitro model of Alzheimer’s disease             | TH ↑                     |            |
|                                                   | DAT ↑                    |            |
|                                                   | IkBa ↑                   |            |
|                                                   | NFkB p65 ↓               |            |
|                                                   | GFAP ↓                   |            |
|                                                   | TNF-α ↓                  |            |
|                                                   | iNOS ↓                   | [74]       |
|                                                   | nNOS ↑                   |            |
|                                                   | Cox-2 ↓                  |            |
|                                                   | Bax ↓                    |            |
|                                                   | Bad ↓                    |            |
|                                                   | Bcl-2 ↑                  |            |
|                                                   | mTOR ↓                   |            |
|                                                   | p70S6K ↓                 |            |
|                                                   | Beclin-1 ↑               |            |
|                                                   | p62 ↑                    |            |
|                                                   | MAP-LC3 ↑                |            |
| Mouse and in vitro model of Parkinson’s disease   | iNOS ↓                   | [74]       |
|                                                   | nNOS ↑                   |            |
|                                                   | Cox-2 ↓                  |            |
|                                                   | Bax ↓                    |            |
|                                                   | Bad ↓                    |            |
|                                                   | Bcl-2 ↑                  |            |
|                                                   | mTOR ↓                   |            |
|                                                   | p70S6K ↓                 |            |
|                                                   | Beclin-1 ↑               |            |
|                                                   | p62 ↑                    |            |
|                                                   | MAP-LC3 ↑                |            |
Table 1. Cont.

| Type of Study | Molecular Targets | References |
|---------------|-------------------|------------|
| Demyelinating diseases (Maturation of Oligodendrocyte Precursor Cells) | | [76,82,83] |
| | Cnr1 ↑ | |
| | Cnr2 ↑ | |
| | Cat ↑ | |
| | Cnp ↑ | |
| | Hmgcr ↑ | |
| | Idi1 ↑ | |
| | Mki67 ↑ | |
| | Mb ↑ | |
| | Ptp1 ↑ | |
| | Scd1 ↑ | |
| | Sod2 ↑ | |
| | Ugt8 ↑ | |
| | PDGFR-α ↑ | |
| Mouse model of Traumatic Brain Injury | Chymase ↓ | [73] |
| | Tryptase ↓ | |
| | GDNF ↑ | |
| | iNOS ↓ | |
| | pJNK ↓ | |
| | Bax ↓ | |
| | Caspase-3 ↓ | |
| | mTOR ↑ | |
| | p70S6K ↑ | |
| | Beclin-1 ↓ | |
| | p62 ↓ | |
| | MAP-LC3 ↓ | |
| | GFAP ↓ | |
| | BDNF ↑ | |
| | GDNF ↑ | |
| | Mast cells ↓ | [78] |
| | Chymase ↓ | |
| | Tryptase ↓ | |
| | Bax ↓ | |
| | Bcl-2 ↑ | |
Table 1. Cont.

| Type of Study                              | Molecular Targets | References |
|--------------------------------------------|-------------------|------------|
| Mouse model of Autism                      | IkBa †            | [79]       |
|                                            | NFkB p65 ↓        |            |
|                                            | iNOS ↓            |            |
|                                            | GFAP ↓            |            |
|                                            | TNF-α ↓           |            |
|                                            | IL-1β ↓           |            |
|                                            | Chymase ↓         |            |
|                                            | Tryptase ↓        |            |
|                                            | Bax ↓             |            |
|                                            | Bcl-2 ↑           |            |
|                                            | BrdU ↑            |            |
|                                            | DCX ↑             |            |
| Mouse model of Multiple Sclerosis (MS)     | SAA1 ↓            | [84]       |
|                                            | TNF-α ↓           |            |
|                                            | IL-1β ↓           |            |
|                                            | IFN-γ ↓           |            |
|                                            | TLR2 ↓            |            |
|                                            | Fpr2 ↓            |            |
|                                            | CD137 ↓           |            |
|                                            | CD3-γ ↓           |            |
|                                            | TCR-ε chain ↓     |            |
|                                            | CB2 ↓             |            |
| Mouse model of Delirium                   | Bax ↓             | [80]       |
|                                            | Bcl-2 ↑           |            |
|                                            | TNF-α ↓           |            |
|                                            | IL-1β ↓           |            |
|                                            | IkBa †            |            |
|                                            | NFkB p65 ↓        |            |
|                                            | Nrf-2 ↑           |            |
|                                            | Mn-SOD ↑          |            |
|                                            | GDNF ↑            |            |

†: increase; ↓: decrease.

6.2. PEA and Polydatin

Polydatin (PLD) (3,5,4-dihydroxystylylate-3-O-β-d-glucopiranoside) is a resveratrol glucoside in which the glycoside group is bound in the C-3 position as a substitute for a hydroxyl group. It is the predominant form in which resveratrol is present in nature. It has been suggested that glucoside can be hydrolyzed to resveratrol already in the duodenum or colon [85]. The biological properties of polydatin have been demonstrated in many studies and they include antioxidant activities, anti-inflammatory [86,87], and neuroprotective [88–90]; moreover, PLD improves microcirculation, inhibits platelet aggregation, asthmatic reactions, and showed microbial resistance and anti-cancer activities. These results led the researchers to evaluate the therapeutic effects of combination of PEA and PLD or the co-micronized compound m-(PEA/PLD). Today endometriosis (EM) is mostly considered to be a chronic inflammatory pathology with multifactorial aetiology, characterized by the implantation and growth of endometrium outside the uterine cavity [91]. Since EM touches 6–10% of the general female population and the frequency of the disease reaches 35–50% in women with
pelvic pain, it is necessary to develop a therapy that is as individual and personalized as possible, while considering the problem in its entirety, in order to improve the quality of life of each patient [92]. Since the main features of the pathogenesis of EM include innate immunity, oxidative stress, and the presence of activated and degranulated mast cells inside the structures, which contribute to the development of pain and hyperalgesia [91,93,94], many researchers decided to use the m-(PEA/PLD) association. This association has proven to be effective and safe, as it has no side effects, both in pre-clinical and clinical studies [95–100]. The effect of PEA-PLD in patients with vestibulodynia that were subjected to transcutaneous electrical nerve stimulation (TENS) was also evaluated in a clinical study. This study showed that the combination PEA-PLD represents a significant additional treatment to TENS, as it is able to down-regulate the hyperactivity of mast cells that are responsible for the proliferation and propagation of the vestibular pain fibers and of hyperalgesia and allodynia [101]. The combination of PEA and PLD appears to be a promising adjunctive therapy in the treatment of primary dysmenorrhoea in adolescents and young women [102]. In a more recent study, it was shown that the m-(PEA/PLD) compound was able to reduce the inflammatory pain that is induced by the injection of carrageenan in the hind paws of rats. Furthermore, it was shown that m-(PEA/PLD), in addition to having peripheral action, also has an effect on downstream effectors that are associated with pain in the spinal cord [103]. The efficacy of the m-(PEA/PLD) compound was also evaluated in a benign testosterone-induced hyperplasia model (BPH). The results of this study reported that the co-micronized compound is able to reduce prostate weight and dihydrotestosterone production in BPH-induced rats. These effects are probably related to the anti-inflammatory and apoptotic effects of m-(PEA/PLD) [104]. Finally, since acute and chronic inflammatory responses are important risk factors for vascular remodeling processes, such as atherosclerosis, arteriosclerosis, and restenosis, it has been demonstrated in a model of vascular damage induced by complete artery ligation left carotid artery the protective effect of the combined treatment of PEA and PLD. In this study, it was clearly demonstrated that PEA/PLD reduces vascular damage, the expression of adhesion molecules, and attenuates the inflammatory process [105]. See the m-(PEA/PLD) molecular targets in Table 2.

Table 2. m-(PEA/PLD) therapeutic actions and molecular targets: in vivo and in vitro study.

| Type of Study | Molecular Targets | References |
|--------------|------------------|------------|
| Rat paw model of carrageenan-induced inflammation (in vivo and in vitro study) | TNF-α ↓ | [103] |
|              | IL-6 ↓           |            |
|              | IL-1β ↓          |            |
|              | MPO ↓            |            |
|              | IκBa ↑           |            |
|              | NFkB p65 ↓       |            |
|              | COX-2 ↓          |            |
|              | iNOS ↓           |            |
|              | Mn-SOD ↑         |            |
|              | MMP9 ↓           |            |
|              | Mast Cell ↓      |            |
|              | NGF ↓            |            |
|              | VEGF ↓           |            |
|              | ICAM-1 ↓         |            |
|              | MPO ↓            |            |
|              | IκBa ↑           |            |
|              | NFkB p65 ↓       |            |
|              | Nitrotyrosine ↓  |            |
|              | PAR ↓            |            |
| Mouse model of surgically-induced Endometriosis | | [99] |
Table 2. Cont.

| Type of Study                          | Molecular Targets | References |
|---------------------------------------|-------------------|------------|
| Rat model of Benign Prostatic Hyperplasia |                   | [104]      |
|                                       | PGE2 ↓            |            |
|                                       | DHT ↓             |            |
|                                       | 5α-reductase 1 ↓  |            |
|                                       | 5α-reductase 2 ↓  |            |
|                                       | IκBa ↑            |            |
|                                       | NFkB p65 ↓        |            |
|                                       | iNOS ↓            |            |
|                                       | COX-2 ↓           |            |
|                                       | Nrf-2 ↑           |            |
|                                       | HO-1 ↑            |            |
|                                       | Mn-SOD ↑          |            |
| Mouse model of Vascular Injury        |                   | [105]      |
|                                       | ICAM-1 ↓          |            |
|                                       | V-CAM ↓           |            |
|                                       | TNF- α ↓          |            |
|                                       | IL-1β ↓           |            |
|                                       | iNOS ↓            |            |
|                                       | IκBa ↑            |            |
|                                       | NFkB p65 ↓        |            |
|                                       | Bax ↓             |            |
|                                       | FAS-Ligand ↓      |            |
|                                       | α-sma ↑           |            |
|                                       | MCP-1 ↑           |            |
|                                       | BrdU ↑            |            |

PEA, Palmitoylethanolamide. ↑ : increase; ↓ : decrease.

6.3. PEA and Quercetin

Quercetin, which belongs to the group of flavonols, is the aglycon component of various glycosides, including rutin and quercitrin. It is one of the most common flavonoids since it can be isolated from numerous plant species including: horse chestnut, calendula, hawthorn, chamomile, hypericum and Ginkgo biloba. Foods that are particularly rich in quercetin are: the caper, red grapes and red wine, red onion, green tea, blueberry, apple, propolis, and celery. It is considered to be a natural inhibitor of various intracellular enzymes and for these properties it has been abundantly studied in the experimental oncological field, in the elucidation of the mechanisms of cell proliferation and carcinogenesis [106,107]. Quercetin is also a natural antioxidant. Among its most important functions are: restoring tocopherol (Vitamin E), after it has turned into a free radical (tocopheryl-radical), detoxifying the cell from the superoxide, and slowing down the production of nitric oxide during inflammation [108].

Currently, the new co-micronized compound consisting of PEA and quercetin has been tested in a few experimental models, including carrageenan-induced paw edema and osteoarthritis (OA) that is induced by sodium moniodoacetate (MIA). OA represents one of the most frequently occurring painful conditions in both humans and small animals. Oxidative stress is considered to be an important etiologic factor in OA, and the antioxidant quercetin has been used with success as an adjunct in human and experimental arthritic diseases. In these studies, PEA-Q has been shown to reduce carrageenan-induced inflammatory responses and hyperalgesia. A reduction in mechanical allodynia with motor improvement and protection of the cartilage was also observed in animals that were treated with MIA. Currently, the translatability of these observations to canine and feline OA pain is currently under study [109]. See the PEA-Q molecular targets in Table 3.
Table 3. 2-pentadecyl-Q (PEA-Q) therapeutic actions and molecular targets: in vivo study.

| Type of Study                                           | Molecular Targets | Reference |
|---------------------------------------------------------|-------------------|-----------|
| Rat paw model of carrageenan-induced inflammation and osteoarthritic pain model | TNF-α ↓, IL-1β ↓, MPO ↓, NGF ↓, MMP-1 ↓, MMP-3 ↓, MMP-9 ↓ | [109] |

↑: increase; ↓: decrease.

6.4. PEA and Silymarin

*Silybum marianum* L., a member of *Carduus marianum* family, is an medicinal plant that has been used for centuries for the treatment of different diseases, such as liver, defensive liver against snake bite and insect stings, mushroom killing, and alcohol abuse [110]. Moreover, this herb has been used for centuries as a natural treatment for upper gastrointestinal tract and digestive problems, menstrual disorders, and varicose veins [111]. However, the very first usage of this herb was for its hepatoprotectant and antioxidant activities. Silymarin is the active component of this herb that exists in its fruit and seeds more than the other parts [112,113]. Silymarin effects have also been indicated in various illnesses of different organs, such as prostate, lungs, central nervous system, kidneys, pancreas, and skin [114]. According to pharmacological studies, silymarin has been accepted as a safe herbal product, since using the physiological doses of silymarin is not toxic. Silymarin has been combined with PEA in an animal model of kidney ischemia and reperfusion due to its antioxidant properties [115]. In this study, various indicators of renal dysfunction and tubular damage were evaluated, but also the inflammatory and apoptotic processes. The results that were obtained by the researchers show how the combined PEA-silymarin treatment was able to reduce histological damage, renal dysfunction, inflammation, and oxidative stress more than single substances. See the PEA-sylmarin molecular targets in Table 4.

Table 4. PEA-sylmarin therapeutic actions and molecular targets: in vivo study.

| Type of Study                              | Molecular Targets         | Reference |
|-------------------------------------------|---------------------------|-----------|
| Mouse model of Kidney Ischemia and Reperfusion | MPO ↓, TNF-α ↓, IL-1β ↓, Nitrite/Nitrate ↓, Superoxide ↓, CuZn SOD ↑, Mn-SOD ↑, Catalase ↑, Nitrotyrosine ↓, PAR ↓, MDA ↓, Chymase ↓, ICAM-1 ↓, p-selectin ↓, IκBα ↑, NFκB p65 ↓, Bax ↓, Bcl-2 ↑ | [115] |

↑: increase; ↓: decrease.
6.5. PEA and Baicalein

Baicalein (5,6,7-trihydroxyflavone) is a flavone that was originally isolated from the roots of *Scutellaria baicalensis* and *Scutellaria lateriflora*. It is also reported in *Oroxylum indicum* (Indian trumpet flower) and Thyme. It is the aglycone of baicalin. Baicalein is one of the active ingredients of Sho-Saiko-To, a Chinese herbal supplement that is believed to enhance liver health. Various studies have proven that Baicalein show antioxidant properties via free radical scavenging capacity and/or enhancing antioxidant system [116]. Moreover, this traditional Chinese herb possesses cardiovascular protective [117], anti-thrombotic [118], anti-inflammatory [119], anti-apoptosis [120], anti-viral [121,122], and anti-cancer effects in vitro [123] and in vivo [124,125]. A combination of PEA and Baicalein has been recently studied in a myocardial I/R injury model [126]. In this study, treatment with PEA-Baicalein was shown to reduce myocardial tissue injury, neutrophil infiltration, markers for expression of mast cell activation, such as chymase and tryptase, and pro-inflammatory cytokine production (TNF-α and IL-1β). Furthermore, treatment with PEA-Baicalein reduced nitrotyrosine and PAR formation, inhibited NF-kB nuclear translocation and modulated apoptosis pathways. See the PEA-Baicalein molecular targets in Table 5.

| Table 5. PEA-Baicalein therapeutic actions and molecular targets: in vivo study. |
|---------------------------------|-----------------|-------------|
| Type of Study | Molecular Targets | Reference |
| Rat model of myocardial I/R injury | MPO ↓ Mast Cell ↓ Chymase ↓ Tryptase ↓ IκBa ↑ NFkB p65 ↓ TNF-α ↓ IL-1β ↓ Bax ↓ Bcl-2 ↑ | [126] |

↑: increase; ↓: decrease.

7. Coffee Identification of a New Form of PEA

2-pentadecyl-2-oxazoline (PEA-OXA) is a new form of PEA that, besides having the classic anti-inflammatory, analgesic, and neuroprotective properties of the latter, also has the ability to modulate the catalytic activity of NAAA amidase, responsible for PEA degradation. Given that PEA is produced as needed and exerts pleiotropic effects on the cells that are involved in inflammation, modulating the activity of specific amidases involved in its degradation, NAAA and FAAH in particular, could represent a way to preserve PEA and help to maintain the cell homeostasis. In a recent study, the LC-MS technique was used to demonstrate the natural presence of PEA-OXA in coffee seeds and infusions [127]. This is the first work in which the natural presence of PEA-OXA is reported in the plant world. Pharmacological studies have been carried out to demonstrate the effects of the administration of PEA-OXA in different experimental models. The effect of PEA-OXA has been investigated in a carrageenan-induced rat inflammation model. PEA-OXA has visibly reduced histological damage, thermal hyperalgesia, inflammation, and oxidative stress. These effects also led to an increase in PEA at the level of the paw. This is probably due to the ability of PEA-OXA to modulate NAAA [128]. The modulation of intracellular NAAA by treatment with PEA-OXA was also evaluated in neuroinflammation models, such as TBI and SCI [129], in neurodegenerative Parkinson’s disease [130], in neuropathic pain after sciatic nerve crush [131], and in vascular dementia [132].
8. Conclusions

Compounds that are present in nature, assimilable through diets, can therefore play an important role in maintaining the well-being of each individual. The possibility through a healthy diet aimed at reinforcing our immune system, for example by enhancing the action of endogenous molecules, such as Aliamides, and, in particular, PEA, can be a valid alternative to the use of anti-inflammatory drugs, or why not, a possible therapy that works in synergy with the latter. PEA shows considerable versatility in counteracting inflammation, in all its formulations and derivatives, such as PEA-um or PEA-OXA. The possibility of using PEA in association with other natural antioxidant molecules, such as the flavonoids, such as Polydatin, Luteolin, Quercetin, or Silyrmarin, demonstrates that PEA is able to act effectively not only individually, but also and above all in synergy with other molecules. It can be concluded that all of these aspects reinforce the concept that sees PEA as an important endogenous balancer of the inflammatory process.

Author Contributions: Conceptualization, A.F.P. and R.S.; formal analysis, A.F.P., R.S. and R.C.; resources, S.C., R.C.; writing—original draft preparation, A.F.P. and R.S.; writing—review and editing, R.C. and S.C., and visualization, A.F.P.; supervision, R.C. and S.C.; project administration, S.C.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments: The authors would like to thank Maria Antonietta Medici for excellent technical assistance, Leonarda Urzi for secretarial and administrative assistance, and Miss Valentina Malvagni for editorial support with the manuscript.

Conflicts of Interest: Salvatore Cuzzocrea is a co-inventor on patent WO2013121449A8 (Epitech Group SpA) which deals with compositions and methods for the modulation of amidases capable of hydrolysing N-acylethanolamines applied in the therapy of inflammatory diseases. Moreover, Cuzzocrea is also a co-inventor with Épitech group on the following patents: 1. EP2821,083, 2. MI2014A001495, 3. 10201500067344.

Abbreviations

- PUFA: polyunsaturated fatty acids
- EPA: Eicosapentaenoic acid
- DHA: docosahexaenoic acid
- NAEs: N-Acylethanolamines
- EE: ethyl ester
- 2-AG: 2-archidonoylglycerol
- AA: arachidonic acid
- AEA: anandamide
- CB1 and CB2: cannabinoid receptor type 1 and 2
- CLA: conjugated linoleic acid
- DAG: diacylglycerol
- FO: fish oil
- KO: krill oil
- LA: linoleic acid
- NAPE: N-acyl-phosphatidylethanolamine
- NAPE-PLD: N-acyl-phosphatidyl-ethanolamine D
- OA: oleic acid
- OEA: N-oleoylethanolamine
- PEA: N-palmitoylethanolamine
- GPR55: G protein coupled receptor 55
- PPAR-a/g: peroxisome proliferatoractivated receptor-a/g
- TRPV1: transient receptor potential of vanilloid type-1
- NAAA: N-acylethanolamine-hydrolysing acid
- FAAH: fatty acid amide hydrolase
References

1. Audial, S.; Bonnotte, B. Inflammation. Rev. Prat. 2015, 65, 403–408. [PubMed]
2. Graziotto, A.; Skaper, S.D.; Fusco, M. Mast cells in chronic inflammation, pelvic pain and depression in women. Gynecol. Endocrinol. 2014, 30, 472–477. [CrossRef] [PubMed]
3. Ostan, R.; Bucci, L.; Capri, M.; Salvioli, S.; Scurti, M.; Pini, E.; Monti, D.; Franceschi, C. Immunosenescence and immunoge genetically of human longevity. Neuroimmunomodulation 2008, 15, 224–240. [CrossRef] [PubMed]
4. Franceschi, C.; Campisi, J. Chronic inflammation (inflamaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69 (Suppl. 1), S4–S9. [CrossRef] [PubMed]
5. Kennedy, B.K.; Berger, S.L.; Brunet, A.; Campisi, J.; Cuervo, A.M.; Epel, E.S.; Franceschi, C.; Lithgow, G.J.; Morimoto, R.I.; Pessin, J.E.; et al. Geroscience: Linking aging to chronic disease. Cell 2014, 159, 709–713. [CrossRef] [PubMed]
6. Islam, M.A.; Alam, F.; Solayman, M.; Khalil, M.I.; Kamal, M.A.; Gan, S.H. Dietary phytochemicals: Natural swords combating inflammation and oxidation-mediated degenerative diseases. Oxid. Med. Cell Longev. 2016, 2016, 5137431. [CrossRef] [PubMed]
7. Grandl, G.; Wolfrum, C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin. Immunopathol. 2018, 40, 215–224. [CrossRef]
8. Arulselvan, P.; Fard, M.T.; Tan, W.S.; Gothai, S.; Fukurazi, S.; Norhaizan, M.E.; Kumar, S.S. Role of antioxidants and natural products in inflammation. Oxid. Med. Cell Longev. 2016, 2016, 5276130. [CrossRef]
9. Raso, G.M.; Russo, R.; Calignano, A.; Meli, R. Palmitoylethanolamide in CNS health and disease. Pharmacol. Res. 2014, 86, 32–41. [CrossRef]
10. Iannotti, F.A.; Di Marzo, V.; Petroso, S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog. Lipid Res. 2016, 62, 107–128. [CrossRef]
11. Riediger, N.D.; Othman, R.A.; Suh, M.; Moghadasian, M.H. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet. Assoc. 2009, 109, 668–679. [CrossRef] [PubMed]
12. Berger, A.; Crozier, G.; Bisogno, T.; Cavaliere, P.; Innis, S.; Di Marzo, V. Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding n-acyl-ethanolamines in piglets. Proc. Natl. Acad. Sci. USA 2001, 98, 6402–6406. [CrossRef] [PubMed]
13. Watanabe, S.; Doshi, M.; Hamazaki, T. N-3 polyunsaturated fatty acid (pufa) deficiency elevates and n-3 pufa enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot. Essent. Fat. Acids 2003, 69, 51–59. [CrossRef] [PubMed]
14. Matias, I.; Carta, G.; Murru, E.; Petroso, S.; Banni, S.; Di Marzo, V. Effect of polyunsaturated fatty acids on endocannabinoid and n-acyl-ethanolamine levels in mouse adipocytes. Biochim. Biophys. Acta 2008, 1781, 52–60. [CrossRef] [PubMed]
15. Alvheim, A.R.; Malde, M.K.; Osei-Hyiaman, D.; Lin, Y.H.; Pawlosky, R.J.; Madsen, L.; Kristiansen, K.; Froyland, L.; Hibbels, J.R. Dietary linoleic acid elevates endogenous 2-ag and anandamide and induces obesity. Obesity 2012, 20, 1984–1994. [CrossRef] [PubMed]
16. Hutchins-Wiese, H.L.; Li, Y.; Hannon, K.; Watkins, B.A. Hind limb suspension and long-chain omega-3 pufa increase mrrna endocannabinoid system levels in skeletal muscle. J. Nutr. Biochem. 2012, 23, 986–993. [CrossRef] [PubMed]
17. Wood, J.T.; Williams, J.S.; Pandarinathan, L.; Janero, D.R.; Lammi-Keefe, C.J.; Makriyannis, A. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J. Lipid Res. 2010, 51, 1416–1423. [CrossRef] [PubMed]
18. Brown, I.; Cascio, M.G.; Wahle, K.W.; Smoum, R.; Mechoulam, R.; Ross, R.A.; Pertwee, R.G.; Hey, S.D. Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 2010, 31, 1584–1591. [CrossRef]
19. McPartland, J.M.; Glass, M.; Pertwee, R.G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: Interspecies differences. Br. J. Pharmacol. 2007, 152, 583–593. [CrossRef]
20. Schuchardt, J.P.; Schneider, I.; Meyer, H.; Neubronner, J.; von Schacky, C.; Hahn, A. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations-a comparative bioavailability study of fish oil vs. Krill oil. Lipids Health Dis. 2011, 10, 145. [CrossRef]
21. Tsuyama, S.; Oikawa, D.; Tsuji, Y.; Akimoto, Y.; Jikuya, H.; Furuse, M. Dietary conjugated linoleic acid modifies the brain endocannabinoid system in mice. *Natur. Neurosci.* 2009, 12, 155–159. [CrossRef] [PubMed]

22. Chiurchiu, V.; Leuti, A.; Smoum, R.; Mechoulam, R.; Maccarrone, M. Bioactive lipids amidases differentially modulate inflammatory responses of distinct subsets of primary human t lymphocytes. *FASEB J.* 2018, 32, 5716–5723. [CrossRef] [PubMed]

23. Coburn, A.F.; Trulson, M.F.; Moore, L.V. further study of the effect of egg yolk on susceptibility of children to rheumatic infection. *Minerva Med.* 1954, 45, 1534–1536. [PubMed]

24. Long, D.A.; Martin, A.J. Factor in arachis oil depressing sensitivity to tuberculin in b.C.G.-infected guineapigs. *Lancet* 1956, 270, 464–466. [CrossRef]

25. Venables, B.J.; Waggoner, C.A.; Chapman, K.D. N-acyl ethanolamines in seeds of selected legumes. *Phytochemistry* 2005, 66, 1913–1918. [CrossRef] [PubMed]

26. Chapman, K.D.; Venables, B.; Markovic, R.; Blair, R.W., Jr.; Bettinger, C. N-acyl ethanolamines in seeds. Quantification of molecular species and their degradation upon imbibition. *Plant Physiol.* 1999, 120, 1157–1164. [CrossRef] [PubMed]

27. Rawyler, A.J.; Braendle, R.A. N-acyl phosphatidylethanolamine accumulation in potato cells upon energy shortage caused by anoxia or respiratory inhibitors. *Plant Physiol.* 2001, 127, 240–251. [CrossRef] [PubMed]

28. Schuel, H.; Burkman, L.J.; Lippes, J.; Crickard, K.; Forester, E.; Piomelli, D.; Giufrida, A. N-acyl ethanolamines in human reproductive fluids. *Chem. Phys. Lipids* 2002, 121, 211–227. [CrossRef]

29. Lam, P.M.; Marczylo, T.H.; Konje, J.C. Simultaneous measurement of three n-acyl ethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. *Anal. Bioanal. Chem.* 2010, 398, 2089–2097. [CrossRef]

30. Re, G.; Barbero, R.; Miolo, A.; Di Marzo, V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection from tissue inflammation and pain: Potential use in companion animals. *Vet. J.* 2007, 173, 21–30. [CrossRef]

31. Aviello, G.; Matias, I.; Capasso, R.; Petrosino, S.; Borrelli, F.; Orlando, P.; Romano, B.; Capasso, F.; Di Marzo, V.; Izzo, A.A. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. *J. Mol. Med.* 2008, 86, 413–422. [CrossRef] [PubMed]

32. Marshall, D.L.; De Micheli, E.; Bogdanov, M.B.; Wurtman, R.J. Effects of ethanolamine (etn) administration on etn and choline (ch) levels in plasma, brain extracellular fluid (ecf) and brain tissue, and on brain phospholipid levels in rats: An in vivo study. *Neurosci. Res. Commun.* 1996, 18, 87–96. [CrossRef]

33. Shimada, Y.; Morita, T.; Sugiyama, K. Dietary eritadenine and ethanolamine depress fatty acid desaturase activities by increasing liver microsomal phosphatidylethanolamine in rats. *J. Nutr.* 2003, 133, 758–765. [CrossRef] [PubMed]

34. Aloe, L.; Leon, A.; Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. *Agents Actions* 1993, 39, C145–147. [CrossRef] [PubMed]
43. Levi-Montalcini, R.; Skaper, S.D.; Dal Tos, R.; Petrelli, L.; Leon, A. Nerve growth factor: From neurotrophin to neurokinin. *Trends Neurosci.* **1996**, *19*, 514–520. [CrossRef]

44. Facci, L.; Dal Tos, R.; Romanello, S.; Buriani, A.; Skaper, S.D.; Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 3376–3380. [CrossRef] [PubMed]

45. Sugiura, T.; Kondo, S.; Kishimoto, S.; Miyashita, T.; Nakane, S.; Kodaka, T.; Suhara, Y.; Takayama, H.; Waku, K. Evidence that 2-arachidonoylglycerol but not n-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid cb2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in hl-60 cells. *J. Biol. Chem.* **2000**, *275*, 605–612. [CrossRef] [PubMed]

46. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: Inhibition of nitric oxide and cyclo-oxygenase systems. *Br. J. Pharmacol.* **2002**, *137*, 413–420. [CrossRef]

47. Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. *Mol. Pharmacol.* **2005**, *67*, 15–19. [CrossRef] [PubMed]

48. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Geasley, P.J. The orphan receptor gpr55 is a novel cannabinoid receptor. *Br. J. Pharmacol.* **2007**, *152*, 1092–1101. [CrossRef]

49. Di Marzo, V.; Petersson, J.; Andersson, D.A.; Chuang, H.; Sorgard, M.; Di Marzo, V.; Julius, D.; De Petrocellis, L. Palmitoylethanolamide enhances anandamide stimulation of human vanillloid vr1 receptors. *FEBS Lett.* **2001**, *506*, 253–256. [CrossRef]

50. Di Marzo, V.; Melck, D.; Orlando, P.; Bisogno, T.; Zagoory, O.; Bifulco, M.; Vogel, Z.; De Petrocellis, L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. *Biochem. J.* **2001**, *358*, 249–255. [CrossRef]

51. Ho, W.S.; Barrett, D.A.; Randall, M.D. ‘Entourage’ effects of n-palmitoylethanolamide and n-oleoylethanolamide on vasorelaxation to anandamide occur through trpv1 receptors. *Br. J. Pharmacol.* **2008**, *155*, 837–846. [CrossRef] [PubMed]

52. Petrosemi, S.; Schiano Moriello, A.; Cerrato, S.; Fusco, M.; Puigdemont, A.; De Petrocellis, L.; Di Marzo, V. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoylglycerol and potentiates its actions at trpv1 cation channels. *Br. J. Pharmacol.* **2016**, *173*, 1154–1162. [CrossRef] [PubMed]

53. Zygmun, P.M.; Peterson, J.; Andersson, D.A.; Chuang, H.; Sorgard, M.; Di Marzo, V.; Julius, D.; Hogestatt, E.D. Vanillloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature* **1995**, *370*, 450–452. [CrossRef] [PubMed]

54. Zygmun, P.M.; Ermund, A.; Movahed, P.; Andersson, D.A.; Simonsen, C.; Jonsson, B.A.; Blomgren, A.; Birnir, B.; Bevan, S.; Eschalier, A.; et al. Monoacylglycerols activate trpv1-a link between phospholipase c and trpv1. *PLoS ONE* **2013**, *8*, e81618. [CrossRef]

55. Guida, F.; Luongo, L.; Boccella, S.; Giordano, M.E.; Romano, R.; Bellini, G.; Manzo, I.; Furiano, A.; Rizzo, A.; Imperatore, R.; et al. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: Involvement of the cb2 receptor. *Sci. Rep.* **2017**, *7*, 375. [CrossRef] [PubMed]

56. Ambrosino, P.; Soldovieri, M.V.; Russo, C.; Taglialetela, M. Activation and desensitization of trpv1 channels in sensory neurons by the pparalpha agonist palmitoylethanolamide. *Br. J. Pharmacol.* **2013**, *168*, 1430–1444. [CrossRef] [PubMed]

57. Ambrosino, P.; Soldovieri, M.V.; De Maria, M.; Russo, C.; Taglialetela, M. Functional and biochemical interaction between pparalpha receptors and trpv1 channels: Potential role in pparalpha agonists-mediated analgesia. *Pharmacol. Res.* **2014**, *87*, 113–122. [CrossRef]

58. Skaper, S.D.; Facci, L.; Barbierato, M.; Zasso, M.; Bruschetta, G.; Impellizzeri, D.; Cuzzocrea, S.; Giusti, P. N-palmitoylethanolamine and neuroinflammation: A novel therapeutic strategy of resolution. *Mol. Neurobiol.* **2015**, *52*, 1034–1042. [CrossRef]

59. Impellizzeri, D.; Bruschetta, G.; Cordaro, M.; Crupi, R.; Siracusa, R.; Esposito, E.; Cuzzocrea, S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. *J. Neuroinflamm.* **2011**, *8*, 136. [CrossRef]

60. Ferracane, R.; Graziani, G.; Gallo, M.; Fogliano, V.; Riti, M. Metabolic profile of the bioactive compounds of burdock (arctium lappa) seeds, roots and leaves. *J. Pharm. Biomed. Anal.* **2010**, *51*, 399–404. [CrossRef]
61. Miean, K.H.; Mohamed, S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. *J. Agric. Food Chem.* 2001, 49, 3106–3112. [CrossRef] [PubMed]

62. Chen, H.Q.; Jin, Z.Y.; Wang, X.J.; Xu, X.M.; Deng, L.; Zhao, J.W. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. *Neurosci. Lett.* 2008, 448, 175–179. [CrossRef] [PubMed]

63. Lopez-Lazaro, M. Distribution and biological activities of the flavonoid luteolin. *Mini Rev. Med. Chem.* 2009, 9, 31–59. [CrossRef] [PubMed]

64. Romanova, D.; Vachalkova, A.; Cipak, L.; Ovesna, Z.; Rauko, P. Study of antioxidant effect of apigenin, luteolin and quercetin by DNA protective method. *Neoplasma* 2001, 48, 104–107. [PubMed]

65. Ghanta, S.; Banerjee, A.; Poddar, A.; Chattopadhyay, S. Oxidative DNA damage preventive activity and antioxidant potential of stevia rebaudiana (bertoni) bertoni, a natural sweetener. *J. Agric. Food Chem.* 2007, 55, 10962–10967. [CrossRef] [PubMed]

66. Harris, G.K.; Qian, Y.; Leonard, S.S.; Sbarra, D.C.; Shi, X. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-e2 formation in raw 264.7 cells. *J. Nutr.* 2006, 136, 1517–1521. [CrossRef] [PubMed]

67. Xagorari, A.; Papapetropoulos, A.; Maurmatis, A.; Economou, M.; Fotsis, T.; Roussos, C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. *J. Pharmacol. Exp. Ther.* 2001, 296, 181–187. [PubMed]

68. Riachi, L.G.; De Maria, C.A. Peppermint antioxidants revisited. *Food Chem.* 2015, 176, 72–81. [CrossRef]

69. Chen, C.Y.; Peng, W.H.; Tsai, K.D.; Hsu, S.L. Luteolin suppresses inflammation-associated gene expression by blocking nf-kappab and ap-1 activation pathway in mouse alveolar macrophages. *Life Sci.* 2007, 81, 1602–1614. [CrossRef]

70. Crupi, R.; Paterniti, I.; Ahmad, A.; Campolo, M.; Esposito, E.; Cuzzocrea, S. Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. *CNS Neurol. Disord. Drug Targets* 2013, 12, 989–1001. [CrossRef]

71. Paterniti, I.; Impellizzeri, D.; Di Paola, R.; Navarra, M.; Cuzzocrea, S.; Esposito, E. A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. *J. Neuroinflamm.* 2013, 10, 91. [CrossRef] [PubMed]

72. Siracusa, R.; Paterniti, I.; Bruschetta, G.; Cordaro, M.; Impellizzeri, D.; Crupi, R.; Cuzzocrea, S.; Esposito, E. The association of palmitoylethanolamide with luteolin decreases autophagy in spinal cord injury. *Mol. Neurobiol.* 2016, 53, 3783–3792. [CrossRef] [PubMed]

73. Cordaro, M.; Impellizzeri, D.; Paterniti, I.; Bruschetta, G.; Siracusa, R.; De Stefano, D.; Cuzzocrea, S.; Esposito, E. Neuroprotective effects of co-ultracepalut on secondary inflammatory process and autophagy involved in traumatic brain injury. *J. Neurotrauma* 2016, 33, 132–146. [CrossRef] [PubMed]

74. Siracusa, R.; Paterniti, I.; Impellizzeri, D.; Cordaro, M.; Crupi, R.; Navarra, M.; Cuzzocrea, S.; Esposito, E. The association of palmitoylethanolamide with luteolin decreases neuroinflammation and stimulates autophagy in parkinson’s disease model. *CNS Neurol. Disord. Drug Targets* 2015, 14, 1350–1365. [CrossRef] [PubMed]

75. Paterniti, I.; Cordaro, M.; Campolo, M.; Siracusa, R.; Cornelius, C.; Navarra, M.; Cuzzocrea, S.; Esposito, E. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental alzheimer’s disease models: The control of neuroinflammation. *CNS Neurol. Disord. Drug Targets* 2014, 13, 1530–1541. [CrossRef]

76. Barbierato, M.; Facci, L.; Marinelli, C.; Zullo, M.; Argentini, C.; Skaper, S.D.; Giusti, P. Co-ultramicronized palmitoylethanolamide/luteolin promotes the maturation of oligodendrocyte precursor cells. *Sci. Rep.* 2015, 5, 16676. [CrossRef]

77. Impellizzeri, D.; Esposito, E.; Di Paola, R.; Ahmad, A.; Campolo, M.; Peli, A.; Morittu, V.M.; Britti, D.; Cuzzocrea, S. Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type ii in mice. *Arthritis Res. Ther.* 2013, 15, R192. [CrossRef]

78. Caltagirone, C.; Cisari, C.; Schievano, C.; Di Paola, R.; Cordaro, M.; Bruschetta, G.; Esposito, E.; Cuzzocrea, S.; Stroke Study, G. Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: From rodent to man. *Stroke Res. Tech.* 2016, 7, 54–69. [CrossRef]

79. Bertolino, B.; Crupi, R.; Impellizzeri, D.; Bruschetta, G.; Cordaro, M.; Siracusa, R.; Esposito, E.; Cuzzocrea, S. Beneficial effects of co-ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism. *CNS Neurosci. Ther.* 2017, 23, 87–98. [CrossRef]
80. Ly, T.; Liu, Y.; Li, G.; Wang, X.; Zeng, Z.; Cai, S.; Li, F.; Chen, Z. Polydatin attenuates ipopolysaccharide-induced acute lung injury in rats. *Int. J. Clin. Exp. Pathol.* 2014, 7, 8401–8410. [CrossRef]

81. Du, Q.H.; Peng, C.; Zhang, H. Polydatin: A review of pharmacology and pharmacokinetics. *Pharm. Biol.* 2013, 51, 1347–1354. [CrossRef]

82. Khan, K.N.; Kitajima, M.; Hiraki, K.; Fujishita, A.; Sekine, I.; Ishimaru, T.; Masuzaki, H. Immunopathogenesis of pelvic endometriosis: Role of hepatocyte growth factor, macrophages and ovarian steroids. *Am. J. Reprod. Immunol.* 2008, 60, 383–404. [CrossRef] [PubMed]

83. Huang, H.Y. Medical treatment of endometriosis. *Chang. Gung Med. J.* 2008, 31, 431–440. [PubMed]

84. Milewski, L.; Barcz, E.; Dziunycz, P.; Radomska, D.; Kaminski, P.; Roszkowski, P.I.; Korczak-Kowalska, G.; Malejczyk, J. Association of leptin with inflammatory cytokines and lymphocyte subpopulations in peritoneal fluid of patients with endometriosis. *J. Reprod. Immunol.* 2008, 79, 111–117. [CrossRef] [PubMed]

85. Anaf, V.; Chapron, C.; El Nakadi, I.; De Moor, V.; Simonart, T.; Noel, J.C. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. *Fertil. Steril.* 2006, 86, 1336–1343. [CrossRef] [PubMed]

86. Fang, Q.; Li, Z.; Zhang, Y.; Zeng, W.; Cai, M.; Wang, H. Effects of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2010, 150, 76–79. [CrossRef] [PubMed]

87. Cobelli, L.; Castaldi, M.A.; Giordano, V.; Trabucco, E.; De Franciscis, P.; Torella, M.; Colacurci, N. Effectiveness of the association micronized n-palmitytoylethanolamine (pea)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: A pilot study. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2011, 158, 82–86. [CrossRef]

88. Giugliano, E.; Cagnazzo, E.; Soave, I.; Lo Monte, G.; Wenger, J.M.; Marci, R. The adjuvant use of n-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2013, 168, 209–213. [CrossRef]
98. Lo Monte, G.; Soave, I.; Marci, R. Administration of micronized palmitoylethanolamide (pea)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: Preliminary results. *Minerva Ginecol.* **2013**, *65*, 453–463.

99. Di Paola, R.; Fusco, R.; Gugliandolo, E.; Crupi, R.; Evangelista, M.; Gransen, R.; Cuzzocrea, S. Co-micronized palmitoylethanolamide/polydatin treatment causes endometriotic lesion regression in a rodent model of surgically induced endometriosis. *Front. Pharmacol.* **2016**, *7*, 382. [CrossRef]

100. Indraccolo, U.; Indraccolo, S.R.; Mignini, F. Micronized palmitoylethanolamide/trans-polydatin treatment of endometriosis-related pain: A meta-analysis. *Ann. Ist. Super. Sanità* **2017**, *53*, 125–134.

101. Murina, F.; Graziottin, A.; Felice, R.; Radici, G.; Tognocchi, C. Vestibulodynia: Synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. *J. Low Genit. Tract Dis.* **2013**, *17*, 111–116. [CrossRef] [PubMed]

102. Tartaglia, E.; Armentano, M.; Giugliano, B.; Sena, T.; Giuliano, P.; Mastrantonio, P. Effectiveness of the association n-palmitoylethanolamine and transpolydatin in the treatment of primary dysmenorrhea. *J. Pediatr. Adolesc. Gynecol.* **2015**, *28*, 447–450. [CrossRef]

103. Esposito, E.; Impellizzeri, D.; Bruschetta, G.; Cordaro, M.; Siracusa, R.; Gugliandolo, E.; Crupi, R.; Cuzzocrea, S. A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. *Eur. J. Pharmacol.* **2016**, *782*, 107–118. [CrossRef] [PubMed]

104. Cordaro, M.; Impellizzeri, D.; Siracusa, R.; Gugliandolo, E.; Fusco, R.; Inferrera, A.; Esposito, E.; Di Paola, R.; Cuzzocrea, S. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. *Toxicol. Appl. Pharmacol.* **2017**, *329*, 231–240. [CrossRef] [PubMed]

105. Gugliandolo, E.; Fusco, R.; Biundo, F.; D’Amico, R.; Benedetto, F.; Di Paola, R.; Cuzzocrea, S. Palmitoylethanolamide and polydatin combination reduces inflammation and oxidative stress in vascular injury. *Pharmacol. Res.* **2017**, *123*, 83–92. [CrossRef]

106. Ranelletti, F.O.; Maggiano, N.; Serra, F.G.; Ricci, R.; Larocca, L.M.; Lanza, P.; Scambia, G.; Fattorossi, A.; Capelli, A.; Piantelli, M. Quercetin inhibits p21-ras expression in human colon cancer cell lines and in primary colorectal tumors. *Int. J. Cancer* **2000**, *85*, 438–445. [CrossRef]

107. Wang, H.K. The therapeutic potential of flavonoids. *Expert Opin. Investig. Drugs* **2000**, *9*, 2103–2119. [CrossRef]

108. Schmitt, C.A.; Dirsch, V.M. Modulation of endothelial nitric oxide by plant-derived products. *Nitric Oxide* *Biol. Chem.* **2009**, *21*, 77–91. [CrossRef]

109. Britti, D.; Crupi, R.; Impellizzeri, D.; Gugliandolo, E.; Fusco, R.; Schieveno, C.; Morittu, V.M.; Evangelista, M.; Di Paola, R.; Cuzzocrea, S. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. *BMC Vet. Res.* **2017**, *13*, 229. [CrossRef]

110. Kren, V.; Walterova, D. Silybin and silymarin-new effects and applications. *Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech. Repub.* **2005**, *149*, 29–41. [CrossRef]

111. Saller, R.; Melzer, J.; Reichling, J.; Brignoli, R.; Meier, R. An updated systematic review of the pharmacology of silymarin. *Complement. Med. Res.* **2007**, *14*, 70–80. [CrossRef] [PubMed]

112. Basiglio, C.L.; Sanchez Pozzi, E.J.; Mottino, A.D.; Roma, M.G. Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. *Chem. Biol. Interact.* **2009**, *179*, 297–303. [CrossRef] [PubMed]

113. Gazak, R.; Walterova, D.; Kren, V. Silybin and silymarin-new and emerging applications in medicine. *Curr. Med. Chem.* **2007**, *14*, 315–338. [CrossRef] [PubMed]

114. Impellizzeri, D.; Bruschetta, G.; Ahmad, A.; Crupi, R.; Siracusa, R.; Di Paola, R.; Paterniti, I.; Prosdocimi, M.; Esposito, E.; Cuzzocrea, S. Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion. *Eur. J. Pharmacol.* **2015**, *762*, 136–149. [CrossRef] [PubMed]

115. Gao, Z.; Huang, K.; Yang, X.; Xu, H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of scutellaria baicalensis georgii. *Biochim. Biophys. Acta* **1999**, *1472*, 643–650. [CrossRef]
117. Wang, C.Z.; Mehendale, S.R.; Yuan, C.S. Commonly used antioxidant botanicals: Active constituents and their potential role in cardiovascular illness. *Am. J. Chin. Med.* 2007, 35, 543–558. [CrossRef]

118. Huang, Y.; Tsang, S.Y.; Yao, X.; Chen, Z.Y. Biological properties of baicalein in cardiovascular system. *Curr. Drug Targets Cardiovasc. Haematol. Disord.* 2005, 5, 177–184. [CrossRef]

119. Chi, Y.S.; Lim, H.; Park, H.; Kim, H.P. Effects of wogonin, a plant flavone from scutellaria radix, on skin inflammation: In vivo regulation of inflammation-associated gene expression. *Biochem. Pharmacol.* 2003, 66, 1271–1278. [CrossRef]

120. Ma, Z.; Otsuyama, K.; Liu, S.; Abroun, S.; Ishikawa, H.; Tsuyama, N.; Obata, M.; Li, F.J.; Zheng, X.; Maki, Y.; et al. Baicalein, a component of scutellaria radix from huang-lian-jie-du-tang (hljdt), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. *Blood* 2005, 105, 3312–3318. [CrossRef]

121. Ma, S.C.; Du, J.; But, P.P.; Deng, X.L.; Zhang, Y.W.; Ooi, V.E.; Xu, H.X.; Lee, S.H.; Lee, S.F. Antiviral chinese medicinal herbs against respiratory syncytial virus. *J. Ethnopharmacol.* 2002, 79, 205–211. [CrossRef]

122. Wu, J.A.; Attele, A.S.; Zhang, L.; Yuan, C.S. Anti-hiv activity of medicinal herbs: Usage and potential development. *Am. J. Chin. Med.* 2001, 29, 69–81. [CrossRef] [PubMed]

123. Motoo, Y.; Sawabu, N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. *Cancer Lett.* 1994, 86, 91–95. [CrossRef]

124. Zhang, D.Y.; Wu, J.; Ye, F.; Xue, L.; Jiang, S.; Yi, J.; Zhang, W.; Wei, H.; Sung, M.; Wang, W.; et al. Inhibition of cancer cell proliferation and prostaglandin e2 synthesis by scutellaria baicalensis. *Cancer Res.* 2003, 63, 4037–4043. [PubMed]

125. Yu, J.; Liu, H.; Lei, J.; Tan, W.; Hu, X.; Zou, G. Antitumor activity of chloroform fraction of scutellaria barbata and its active constituents. *Phytother. Res. Int. J. Devot. Pharmacol. Toxicol. Ecol. Nat. Prod. Derivo.* 2007, 21, 817–822.

126. D’Amico, R.; Fusco, R.; Gugliandolo, E.; Cordaro, M.; Siracusa, R.; Impellizzeri, D.; Peritore, A.F.; Crupi, R.; Cuzzocrea, S.; Di Paola, R. Effects of a new compound containing palmitoylethanolamide and baicalein in myocardial ischaemia/reperfusion injury in vivo. *Phytochem.* 2019, 54, 27–42. [CrossRef] [PubMed]

127. Impellizzeri, D.; Cordaro, M.; Bruschetta, G.; Crupi, R.; Pascali, J.; Alfonso, D.; Marcolongo, G.; Cuzzocrea, S. 2-pentadecyl-2-oxazoline: Identification in coffee, synthesis and activity in a rat model of carrageenan-induced hindpaw inflammation. *Pharmacol. Res.* 2016, 108, 23–30. [CrossRef] [PubMed]

128. Petrosino, S.; Campolo, M.; Impellizzeri, D.; Paterniti, I.; Allara, M.; Gugliandolo, E.; D’Amico, R.; Siracusa, R.; Cordaro, M.; Esposito, E.; et al. 2-pentadecyl-2-oxazoline, the oxazoline of pea, modulates carrageenan-induced acute inflammation. *Front. Pharmacol.* 2017, 8, 308. [CrossRef]

129. Impellizzeri, D.; Cordaro, M.; Bruschetta, G.; Siracusa, R.; Crupi, R.; Esposito, E.; Cuzzocrea, S. N-palmitoylethanolamine-oxazoline as a new therapeutic strategy to control neuroinflammation: Neuroprotective effects in experimental models of spinal cord and brain injury. *J. Neurotrauma* 2017, 34, 2609–2623. [CrossRef]

130. Cordaro, M.; Siracusa, R.; Crupi, R.; Impellizzeri, D.; Peritore, A.F.; D’Amico, R.; Gugliandolo, E.; Di Paola, R.; Cuzzocrea, S. 2-pentadecyl-2-oxazoline reduces neuroinflammatory environment in the mptp model of parkinson disease. *Mol. Neurobiol.* 2018, 55, 9251–9266. [CrossRef]

131. Gugliandolo, E.; D’Amico, R.; Cordaro, M.; Fusco, R.; Siracusa, R.; Crupi, R.; Impellizzeri, D.; Cuzzocrea, S.; Di Paola, R. Effect of pea-oxa on neuropathic pain and functional recovery after sciatic nerve crush. *J. Neuroinflamm.* 2018, 15, 264. [CrossRef] [PubMed]

132. Impellizzeri, D.; Siracusa, R.; Cordaro, M.; Crupi, R.; Peritore, A.F.; Gugliandolo, E.; D’Amico, R.; Petrosino, S.; Evangelista, M.; Di Paola, R.; et al. N-palmitoylethanolamine-oxazoline (pea-oxa): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion. *Neurobiol. Dis.* 2019, 125, 77–91. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).